Target intelligence / Profile preview

DNA polymerase zeta catalytic subunit (REV3-like) (REV3L or Rev3)

Target
REV3L or Rev3
Molecular classification
Enzyme (specifically DNA polymerase), B-family DNA polymerase
01

Overview

DNA polymerase zeta catalytic subunit (REV3-like) is the largest and catalytically active component of Pol ζ, a B-family DNA polymerase that is crucial for translesion DNA synthesis—a pathway allowing DNA replication past lesions or damage that would otherwise stall replication forks. REV3L forms a multi-subunit enzyme complex with REV7 (also MAD2L2), POLD2, and POLD3, enabling tolerance to diverse DNA lesions and promoting genome stability in eukaryotic cells. The holoenzyme has a pentameric ring-like structure, and unlike other B-family DNA polymerases, the exonuclease domain of REV3L is inactive (lacks proofreading). Loss of REV3L function leads to genomic instability and cell death, while its activity is leveraged by cancer cells to survive genotoxic stress, making it a promising—but therapeutically challenging—target.

Other names
REV3L (human gene symbol commonly used)Rev3p (yeast ortholog)DNA polymerase zeta catalytic subunitREV3-like
02

Mechanism of action

Extension step of translesion synthesis—REV3L (Pol ζ) extends primers across beyond replication-blocking DNA lesions, often working with other TLS polymerases (e.g., REV1, Pol η)

03

Biological functions

DNA replication (especially under stress or damage conditions)Translesion DNA synthesis (TLS)DNA repair (error-prone lesion bypass)Genome stability maintenance
04

Disease associations

Cancer (key role in mutagenesis, therapy resistance, and genomic instability)Other (general link to diseases involving DNA repair failure)
05

Safety considerations

Pol ζ deficiency is associated with increased genomic instability and embryonic lethality in mammalsTargeting REV3L risks increased mutation rate, chromosomal aberrations, and tumorigenesis
06

Interacting drugs

No approved drugs directly target REV3L, but experimental inhibitors and DNA-damaging agents may modulate its function; targeting Pol ζ is being explored for cancer therapy
07

Biomarkers

Genomic instability, mutation rates, and expression of REV3L may serve as biomarkers in cancer context

Beyond the preview

Go deeper on DNA polymerase zeta catalytic subunit (REV3-like) (REV3L or Rev3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase zeta catalytic subunit (REV3-like) (REV3L or Rev3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call